Screener
Axsome Therapeutics AXSM AZD7325 — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Axsome Therapeutics’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 5:02 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-064267
The Company accounted for the transaction as an acquisition of an asset, as substantially all the fair value of the assets acquired were concentrated in AZD7325. The Company recorded a charge of $2.3 million in research and development expense, inclusive of the shares acquired, license amendment costs, and direct transaction costs.
ITEM 15. EXHIBITS and FINANCIAL STATEMENT SCHEDULES.
FAQ
- What is Axsome Therapeutics's AZD7325 — research and development expense?
- Axsome Therapeutics (AXSM) reported AZD7325 — research and development expense of $2.3M in Q4 2025.
- What does AZD7325 — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the AZD7325 therapeutic candidate. It encompasses expenses related to clinical trial execution, manufacturing of drug supplies for testing, and specialized personnel costs dedicated to this specific CNS asset. Monitoring this expenditure provides insight into the capital allocation strategy and the pace of clinical progression for this particular pipeline program.
Ask your AI about Axsome Therapeutics's azd7325 — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude